Skip to Content

Alterity Therapeutics Ltd ADR - Stock Quote ATHE

Rating as of

Morningstar's Alterity Therapeutics Ltd ADR Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - ATHE

Alterity Therapeutics Ltd ADR's Company Profile

Business Description

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434).

Contact
460 Bourke Street, Level 3
Melbourne, VIC, 3000, Australia
T +61 393494906
Industry Biotechnology
Most Recent Earnings Jun 30, 2008
Fiscal Year End Jun 30, 2022
Stock Type
Employees 11